File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Immediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: A preliminary study

TitleImmediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: A preliminary study
Authors
Issue Date2001
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.glaucomajournal.com
Citation
Journal Of Glaucoma, 2001, v. 10 n. 2, p. 89-94 How to Cite?
AbstractPurpose: To study the efficacy and safety of diode laser peripheral iridoplasty as a first-line treatment of acute primary angle-closure glaucoma (PACG) without the use of systemic anti-glaucoma medications. Patients and Methods: Nine consecutive patients with acute PACG were recruited into the study. Each patient received topical pilocarpine (4%), timolol (0.5%), apraclonidine (1%), and immediate diode laser peripheral iridoplasty as primary treatment. The intraocular pressures (IOPs) 15, 30, and 60 minutes after diode laser peripheral iridoplasty were documented by Goldmann applanation tonometry. Results: The mean IOP of this group of patients was reduced from 66.3 ± 9.7 mm Hg, before diode laser peripheral iridoplasty, to 36.6 ± 16.4 mm Hg at 15 minutes, 26.3 ± 12.6 mm Hg at 30 minutes, and 18.9 ± 8.4 mm Hg at 60 minutes after diode laser peripheral iridoplasty. In seven of the nine patients, the corneal edema cleared up 1 hour after diode laser peripheral iridoplasty. In the remaining patient, the cornea cleared up 12 hours after diode laser peripheral iridoplasty. No significant complications were encountered. Conclusion: Diode laser peripheral iridoplasty, together with topical antiglaucoma medications without adjunctive systemic carbonic anhydrase inhibitors and hyperosmotic agents, appeared to be effective and safe in controlling the IOP in acute PACG.
Persistent Identifierhttp://hdl.handle.net/10722/176373
ISSN
2015 Impact Factor: 2.102
2015 SCImago Journal Rankings: 1.477
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, JSMen_US
dc.contributor.authorTham, CCYen_US
dc.contributor.authorChua, JKHen_US
dc.contributor.authorLam, DSCen_US
dc.date.accessioned2012-11-26T09:10:52Z-
dc.date.available2012-11-26T09:10:52Z-
dc.date.issued2001en_US
dc.identifier.citationJournal Of Glaucoma, 2001, v. 10 n. 2, p. 89-94en_US
dc.identifier.issn1057-0829en_US
dc.identifier.urihttp://hdl.handle.net/10722/176373-
dc.description.abstractPurpose: To study the efficacy and safety of diode laser peripheral iridoplasty as a first-line treatment of acute primary angle-closure glaucoma (PACG) without the use of systemic anti-glaucoma medications. Patients and Methods: Nine consecutive patients with acute PACG were recruited into the study. Each patient received topical pilocarpine (4%), timolol (0.5%), apraclonidine (1%), and immediate diode laser peripheral iridoplasty as primary treatment. The intraocular pressures (IOPs) 15, 30, and 60 minutes after diode laser peripheral iridoplasty were documented by Goldmann applanation tonometry. Results: The mean IOP of this group of patients was reduced from 66.3 ± 9.7 mm Hg, before diode laser peripheral iridoplasty, to 36.6 ± 16.4 mm Hg at 15 minutes, 26.3 ± 12.6 mm Hg at 30 minutes, and 18.9 ± 8.4 mm Hg at 60 minutes after diode laser peripheral iridoplasty. In seven of the nine patients, the corneal edema cleared up 1 hour after diode laser peripheral iridoplasty. In the remaining patient, the cornea cleared up 12 hours after diode laser peripheral iridoplasty. No significant complications were encountered. Conclusion: Diode laser peripheral iridoplasty, together with topical antiglaucoma medications without adjunctive systemic carbonic anhydrase inhibitors and hyperosmotic agents, appeared to be effective and safe in controlling the IOP in acute PACG.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.glaucomajournal.comen_US
dc.relation.ispartofJournal of Glaucomaen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdrenergic Alpha-Agonists - Therapeutic Useen_US
dc.subject.meshAdrenergic Beta-Antagonists - Therapeutic Useen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshClonidine - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlaucoma, Angle-Closure - Drug Therapy - Surgeryen_US
dc.subject.meshHumansen_US
dc.subject.meshIntraocular Pressureen_US
dc.subject.meshIris - Surgeryen_US
dc.subject.meshLaser Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMiotics - Therapeutic Useen_US
dc.subject.meshPilocarpine - Therapeutic Useen_US
dc.subject.meshTimolol - Therapeutic Useen_US
dc.subject.meshTonometry, Ocularen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleImmediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: A preliminary studyen_US
dc.typeArticleen_US
dc.identifier.emailLai, JSM: laism@hku.hken_US
dc.identifier.authorityLai, JSM=rp00295en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/00061198-200104000-00004-
dc.identifier.pmid11316102-
dc.identifier.scopuseid_2-s2.0-0035052429en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035052429&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume10en_US
dc.identifier.issue2en_US
dc.identifier.spage89en_US
dc.identifier.epage94en_US
dc.identifier.isiWOS:000167947500004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLai, JSM=7401939748en_US
dc.identifier.scopusauthoridTham, CCY=7006081241en_US
dc.identifier.scopusauthoridChua, JKH=7005163724en_US
dc.identifier.scopusauthoridLam, DSC=35500200200en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats